Received Nov 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | FJ987 | — |
a patient got the 2nd dose of Shingrix 16 days after the first one; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 81-year-old male patient who received Herpes zoster (Shingrix) (batch number FJ987, expiry date 16-JUL-2026) for prophylaxis. Concomitant products included VARICELLA ZOSTER VACCINE RGE (CHO) (SHINGRIX). On 28-OCT-2024, the patient received the 2nd dose of Shingrix. On 28-OCT-2024, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: a patient got the 2nd dose of Shingrix 16 days after the first one). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK receipt date: 19-NOV-2025 The pharmacist called to get guidance for the Shingrix vaccine series. A patient got the 2nd dose of Shingrix 16 days after the first one. The reporter wanted to know if the patient required a third dose as a booster or restart the complete series again. The vaccine administration facility was the same as primary reporter. The batch number was not provided and a request for this information has been made.